Substituted asymmetric ureas as modulators of ghrelin receptor activity
US9926337B2 · kind B2 · utility
2Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2016 |
| Grant date | Mar 27, 2018 |
| Priority date | — |
| Expiry date | Dec 2, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I:or pharmaceutically acceptable salts thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.